Analyst Rating Update on Horizon Pharma plc (HZNP)

Horizon Pharma plc (HZNP) has an average broker rating of 1.29, which is interpreted as a Strong Buy, as rated by 7 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Horizon Pharma plc (HZNP) : The most positive equity analysts on Horizon Pharma plc (HZNP) expects the shares to touch $45, whereas, the least positive believes that the stock will trade at $24 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $32.29 with an expected fluctuation of $8.46 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, Morgan Stanley upgrades its outlook on Horizon Pharma plc (NASDAQ:HZNP). The current rating of the shares is Equal-weight, according to the research report released by the firm. Previously, the company had a rating of Underweight. The brokerage firm maintains the price target at $24 per share. The rating by the firm was issued on July 11, 2016.


Horizon Pharma plc (NASDAQ:HZNP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $19.33 and $19.09 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $19.78. The buying momentum continued till the end and the stock did not give up its gains. It closed at $19.76, notching a gain of 1.70% for the day. The total traded volume was 3,665,300 . The stock had closed at $19.43 on the previous day.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.